

# KAMRON LABORATORIES LIMITED

Registered Office : 904, Shapath-1, Opp. Rajpath Club, S. G. Highway,  
Ahmedabad – 380 054, Gujarat, INDIA. Phone: +91-9227510541  
E-mail : info@kamronlabs.com Website: www.kamronlabs.com  
CIN : L24231GJ1988PLC010956



13<sup>th</sup> February, 2021

**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai - 400 001

**Company Code No. 524604**

Dear Sirs,

**Sub: Submission of Unaudited Financial Results for the Quarter  
ended on 31<sup>st</sup> December, 2020**

We refer to our letter dated 1<sup>st</sup> February, 2021 informing the date of Meeting of the Board of Directors of the Company. Please note that the Board of Directors in their meeting held today, have taken on record the Unaudited Financial Results for the quarter ended on 31<sup>st</sup> December, 2020.

We are enclosing herewith copy of the said Unaudited Financial Results for the quarter ended on 31<sup>st</sup> December, 2020 along with Limited Review Report thereon.

This is as per Regulation – 33 of the SEBI (LODR) Regulations, 2015.

Thanking you,

Yours faithfully,  
**For KAMRON LABORATORIES LIMITED**

*Kamlesh J. Laskari*  
**KAMLESH J. LASKARI**  
**MANAGING DIRECTOR**  
**(DIN : 00461198)**



Encl: As above.

# KAMRON LABORATORIES LIMITED

Registered Office : 904, Shapath-1, Opp. Rajpath Club, S. G. Highway,  
Ahmedabad – 380 054, Gujarat, INDIA. Phone: +91-9227510541  
E-mail : info@kamronlabs.com Website: www.kamronlabs.com  
CIN : L24231GJ1988PLC010956



## KAMRON

### STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 31<sup>ST</sup> DECEMBER, 2020

(Rs. In lakh)

Particulars	Quarter ended on			9 Months ended on (Cumulative)		Previous Year ended on 31-03-2020
	31-12-2020	30-09-2020	31-12-2019	31-12-2020	31-12-2019	
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
(Refer Notes Below)						
1 Revenue from operations	163.47	125.93	178.92	425.61	522.03	659.13
2 Other income	0	0.12	1.04	0.12	1.71	2.34
3 Total Income (1+2)	163.47	126.05	179.96	425.73	523.74	661.47
4 Expenses						
a. Cost of Materials consumed	-	-	53.69	-	54.43	54.43
b. Purchases of stock-in-trade	102.72	20.32	41.37	181.24	224.14	270.14
c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(17.40)	22.32	180.97	18.54	189.17	162.94
d. Employee benefits expense	41.99	44.00	44.14	114.55	119.28	194.49
e. Finance costs	0.25	0.41	0.23	0.90	0.24	2.02
f. Depreciation & amortisation expense	28.68	28.71	8.90	86.05	46.71	42.26
g. Other expenses	47.15	44.65	72.94	124.77	211.73	310.28
<b>Total Expenses</b>	<b>203.39</b>	<b>160.41</b>	<b>402.24</b>	<b>526.05</b>	<b>845.70</b>	<b>1036.56</b>
5 Profit / (Loss) before exceptional items and tax (3-4)	(39.92)	(34.36)	(222.28)	(100.32)	(321.96)	(375.09)
6 Exceptional items	-	-	18.16	-	18.16	24.34
7 Profit / (Loss) before tax (5+6)	(39.92)	(34.36)	(204.12)	(100.32)	(303.80)	(350.75)
8 Tax expense:						
Current tax	-	-	-	-	-	25.00
Deferred tax	-	-	-	-	-	0.71
9 Profit (Loss) for the period from continuing operations (7-8)	(39.92)	(34.36)	(204.12)	(100.32)	(303.80)	(376.46)
10 Profit/(loss) from discontinuing operations before Tax	-	-	-	-	-	-
11 Tax expense of discontinuing operations	-	-	-	-	-	-
12 Profit/(loss) from Discontinuing operations (after tax) (10-11)	-	-	-	-	-	-
13 Profit / (Loss) for the period (9+12)	(39.92)	(34.36)	(204.12)	(100.32)	(303.80)	(376.46)



FOR, KAMRON LABORATORIES LTD.

*Kamrun Khan*  
MANAGING DIRECTOR

# KAMRON LABORATORIES LIMITED

Registered Office : 904, Shapath-1, Opp. Rajpath Club, S. G. Highway,  
Ahmedabad – 380 054, Gujarat, INDIA. Phone: +91-9227510541  
E-mail : info@kamronlabs.com Website: www.kamronlabs.com  
CIN : L24231GJ1988PLC010956



## KAMRON

Particulars	Quarter ended on			9 Months ended on (Cumulative)		Previous Year ended on 31-03-2020
	31-12-2020	30-09-2020	31-12-2019	31-12-2020	31-12-2019	
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
14 Other Comprehensive Income						
Items that will not be reclassified subsequently to profit or loss						-
Income tax relating to items that will not be reclassified to profit or loss						
Items that will be reclassified subsequently to profit or loss						
Income tax relating to items that will be reclassified to profit or loss						
<b>Other Comprehensive Income, net of tax</b>						
15 <b>Total Comprehensive Income for the period (13+14)</b>	<b>(39.92)</b>	<b>(34.36)</b>	<b>(204.12)</b>	<b>(100.32)</b>	<b>(303.80)</b>	<b>(376.46)</b>
16 Paid-up equity shares capital (Face Value per share Rs. 10/-)	<b>585</b>	<b>585.00</b>	<b>585.00</b>	<b>585</b>	<b>585.00</b>	<b>585.00</b>
17 Reserves excluding Revaluation Reserves						
18 Earnings Per Share of Rs. <u>10</u> each (for continuing operations)						
- Basic	(0.68)	(0.59)	(0.35)	(1.71)	(0.52)	(6.45)
- Diluted	(0.68)	(0.59)	(0.35)	(1.71)	(0.52)	(6.45)
19 Earnings Per Share of Rs. <u>10</u> each (for discontinued operations)						
- Basic						
- Diluted						
20 Earnings Per Share of Rs. <u>10</u> each (for discontinued & continuing operations)						
- Basic	(0.68)	(0.59)	(0.35)	(1.71)	(0.52)	(6.45)
- Diluted	(0.68)	(0.59)	(0.35)	(1.71)	(0.52)	(6.45)



FOR, KAMRON LABORATORIES LTD.

*Kamrun* | *Carikan*  
MANAGING DIRECTOR

# KAMRON LABORATORIES LIMITED

Registered Office : 904, Shapath-1, Opp. Rajpath Club, S. G. Highway,  
Ahmedabad – 380 054, Gujarat, INDIA. Phone: +91-9227510541  
E-mail : info@kamronlabs.com Website: www.kamronlabs.com  
CIN : L24231GJ1988PLC010956



**KAMRON**

## Notes:

1	The Company is operating only in one segment which comprise of Marketing of Pharmaceuticals Products and Nutraceuticals and Dietary Supplements.
2	The Company does not have any subsidiary / associate.
3	Provision for taxation/deferred taxation, if any, will be made at the year end.
4	Figures, wherever required, are regrouped / rearranged.
5	The above results have been reviewed by audit committee and approved by Board of Directors of Company at its meeting held on 13 February, 2021.



Date: 13 February, 2021  
Place: Ahmedabad

For **KAMRON LABORATORIES LIMITED**  
FOR, **KAMRON LABORATORIES LTD.**

*Kamlesh J. Laskari*

**KAMLESH J. LASKARI**  
**MANAGING DIRECTOR**  
**(DIN : 00461198 )**

LIMITED REVIEW REPORT

Review report to Board of Directors of Kamron Laboratories Ltd

We have reviewed the accompanying statement of unaudited standalone financial results of Kamron Laboratories Ltd for the period ended 31st December 2020, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, as amended ("the Listing Regulations").

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors of the Company, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement(s). A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M/s Rangwala & Co.  
Chartered Accountants  
(Firm's Registration No. 115833W)

  
ALIAKBAR TIMBAWALA  
Partner  
(Membership No. 180746)  
(UDIN: 21031268AAAAAZ6577)



Date: 13/02/2021  
Place: Ahmedabad